Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines

Loredana Serpe, Marilena Guido, Roberto Canaparo, Elisabetta Muntoni, Roberta Cavalli, Patrizia Panzanelli, Carlo Della Pepa, Alessandro Bargoni, Alessandro Mauro, Maria Rosa Gasco, Mario Eandi, Gian Paolo Zara

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx®) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC 50, values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.

Original languageEnglish
Pages (from-to)3062-3069
Number of pages8
JournalJournal of Nanoscience and Nanotechnology
Volume6
Issue number9-10
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Drug Compounding
Cytotoxicity
Doxorubicin
Drug products
Lipids
Cells
Nanoparticles
Cell Line
Pharmaceutical Preparations
Neoplasms
Liposomes
High performance liquid chromatography
Cell growth
HT29 Cells
Drug Carriers
Trypan Blue
Retinoblastoma
Assays
Dyes
Glioblastoma

Keywords

  • Doxorubicin
  • Liposomes
  • Solid Lipid Nanoparticles

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Materials Science (miscellaneous)
  • Engineering (miscellaneous)

Cite this

Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. / Serpe, Loredana; Guido, Marilena; Canaparo, Roberto; Muntoni, Elisabetta; Cavalli, Roberta; Panzanelli, Patrizia; Pepa, Carlo Della; Bargoni, Alessandro; Mauro, Alessandro; Gasco, Maria Rosa; Eandi, Mario; Zara, Gian Paolo.

In: Journal of Nanoscience and Nanotechnology, Vol. 6, No. 9-10, 09.2006, p. 3062-3069.

Research output: Contribution to journalArticle

Serpe, L, Guido, M, Canaparo, R, Muntoni, E, Cavalli, R, Panzanelli, P, Pepa, CD, Bargoni, A, Mauro, A, Gasco, MR, Eandi, M & Zara, GP 2006, 'Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines', Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 3062-3069. https://doi.org/10.1166/jnn.2006.423
Serpe, Loredana ; Guido, Marilena ; Canaparo, Roberto ; Muntoni, Elisabetta ; Cavalli, Roberta ; Panzanelli, Patrizia ; Pepa, Carlo Della ; Bargoni, Alessandro ; Mauro, Alessandro ; Gasco, Maria Rosa ; Eandi, Mario ; Zara, Gian Paolo. / Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. In: Journal of Nanoscience and Nanotechnology. 2006 ; Vol. 6, No. 9-10. pp. 3062-3069.
@article{b71e9ba6a41f414da120a9b291bc8368,
title = "Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines",
abstract = "The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx{\circledR}) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC 50, values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.",
keywords = "Doxorubicin, Liposomes, Solid Lipid Nanoparticles",
author = "Loredana Serpe and Marilena Guido and Roberto Canaparo and Elisabetta Muntoni and Roberta Cavalli and Patrizia Panzanelli and Pepa, {Carlo Della} and Alessandro Bargoni and Alessandro Mauro and Gasco, {Maria Rosa} and Mario Eandi and Zara, {Gian Paolo}",
year = "2006",
month = "9",
doi = "10.1166/jnn.2006.423",
language = "English",
volume = "6",
pages = "3062--3069",
journal = "Journal of Nanoscience and Nanotechnology",
issn = "1533-4880",
publisher = "American Scientific Publishers",
number = "9-10",

}

TY - JOUR

T1 - Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines

AU - Serpe, Loredana

AU - Guido, Marilena

AU - Canaparo, Roberto

AU - Muntoni, Elisabetta

AU - Cavalli, Roberta

AU - Panzanelli, Patrizia

AU - Pepa, Carlo Della

AU - Bargoni, Alessandro

AU - Mauro, Alessandro

AU - Gasco, Maria Rosa

AU - Eandi, Mario

AU - Zara, Gian Paolo

PY - 2006/9

Y1 - 2006/9

N2 - The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx®) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC 50, values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.

AB - The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx®) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC 50, values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.

KW - Doxorubicin

KW - Liposomes

KW - Solid Lipid Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=33750056080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750056080&partnerID=8YFLogxK

U2 - 10.1166/jnn.2006.423

DO - 10.1166/jnn.2006.423

M3 - Article

C2 - 17048519

AN - SCOPUS:33750056080

VL - 6

SP - 3062

EP - 3069

JO - Journal of Nanoscience and Nanotechnology

JF - Journal of Nanoscience and Nanotechnology

SN - 1533-4880

IS - 9-10

ER -